Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509140 | 0.85 | HPGD (0.54) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL12213211 | 0.84 | SMN1; SMN2 (0.50) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL471656 | 0.84 | HPGD (0.50) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL2170651 | 0.82 | HPGD (0.57) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL13666585 | 0.82 | HPGD (0.49) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL471670 | 0.82 | HPGD (0.51) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL471668 | 0.82 | HPGD (0.51) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL18570098 | 0.80 | HSP90AA1 (0.64) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL9171117 | 0.80 | MEN1 (0.52) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL1536288 | 0.80 | HTT (0.55) | HPGDSMN1; SMN2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883650-B1 | Bi-layered neural interface with nerve-facing drug eluting structure | Verily Life Sciences, LLC (US) | 2024-01-30 | — | — | US | claimed |
| US-20220338769-A1 | METHODS AND APPARATUS FOR SUBSTANCE DELIVERY IN AN IMPLANTABLE DEVICE | MCNAIR INTERESTS LTD. | 2022-10-27 | — | — | US | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12605252-B2 | Bone density scan result-matched orthopedic implants and methods of use | AURORA SPINE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | disclosed |
| US-12478481-B2 | Bone density scan result-matched orthopedic implants and methods of use | AURORA SPINE, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250262218-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | Auros Pharma LLC | 2025-08-21 | — | — | US | disclosed |
| CN-120033335-A | High-entropy flame-retardant electrolyte and preparation method and application thereof | 湖北航天化学技术研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-2008063548-A2 | 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7297821-B2 | Fluorine compound and fluorinating agent comprising the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-11-20 | — | — | US | disclosed |
| EP-1813596-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA- DIFLUOROAMINE | National University Corporation Hokkaido University (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060089513-A1 | Fluorine compound and fluorinating agent comprising the compound | HIDAKA TOSHIO | 2006-04-27 | — | — | US | disclosed |
| US-7019173-B2 | Fluorine compound and fluorinating agent comprising the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1422216-A1 | FLUORINE COMPOUND AND FLUORINATING AGENT COMPRISING THE COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040073065-A1 | Fluorine compound and fluorinating agent comprising the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | HPGD 1608/4885SMN1; SMN2 1319/4885MEN1 4885/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | HPGD 1974/4885SMN1; SMN2 1428/4885MEN1 4858/4885 |
| US-12605252-B2 | Bone density scan result-matched orthopedic implants and methods of use | SOST, BMP2, COL2A1 | HPGD 4131/4885SMN1; SMN2 1076/4885MEN1 1522/4885 |
| US-12396981-B2 | Methods of using DMT | PNMT, HTR6, HTR1A | HPGD 2674/4885SMN1; SMN2 370/4885MEN1 1347/4885 |
| US-20250375421-A1 | METHODS OF USING DMT | PNMT, HTR6, HTR1A | HPGD 2674/4885SMN1; SMN2 370/4885MEN1 1347/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | HPGD 77/4885SMN1; SMN2 1795/4885MEN1 1853/4885 |
| US-20060089513-A1 | Fluorine compound and fluorinating agent comprising the compound | AFF1, AFF2, RER1 | HPGD 4000/4885SMN1; SMN2 2281/4885MEN1 611/4885 |
| US-20040073065-A1 | Fluorine compound and fluorinating agent comprising the compound | AFF1, RER1, AFF2 | HPGD 4060/4885SMN1; SMN2 2298/4885MEN1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.